Today: 14 May 2026
Browse Category

Pharmaceuticals 24 November 2025 - 30 November 2025

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly closed Friday at $1,075 per share, capping a November surge that pushed its market value above $1 trillion—the first for a pharmaceutical company. Shares rose about 26% in November and are up over 40% in 2025. Investors are debating whether the stock, trading at a trailing P/E of 70, can sustain further gains amid strong demand for its GLP-1 obesity drugs.
30 November 2025
··
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie shares closed at $227.70 on November 28, near record highs after a 31.7% year-to-date gain. The company secured a major reimbursement win in Canada for Skyrizi in ulcerative colitis. Institutional investors reported changes in AbbVie holdings. Analysts questioned whether the stock remains undervalued after its recent rally.
29 November 2025
···
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly shares closed at $1,075.47 on November 28, down 2.6%, pulling the S&P 500 healthcare sector lower despite gains in the broader market. The stock remains up over 30% for November and more than 40% year-to-date, with a market cap around $1 trillion. JPMorgan raised its price target to $1,150. Recent gains followed strong Q3 earnings and surging sales of Mounjaro and Zepbound.
29 November 2025
··
Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson shares closed just below a 52-week high near $208 on November 28, giving the company a $500 billion market cap. The stock is up 17.6% over three months and 43% year-to-date, far outpacing the S&P 500. Recent moves include a $3.05 billion Halda Therapeutics acquisition and plans to spin off DePuy Synthes. Norway’s sovereign wealth fund has taken a multibillion-dollar stake.
28 November 2025
··
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK shares traded near 12-month highs on November 28, 2025, with London shares at 1,806p, up 0.2%, and New York ADRs at $48.02, just below their yearly peak. MarketBeat issued a fresh “Hold” consensus from seven analysts, with an average 12-month price target of $44.13, under current levels. The stock’s recent gains follow continued share buybacks and a busy drug pipeline.
28 November 2025
··
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk shares rebounded sharply on 26 November, with U.S. ADRs up 3.7% to $48.79 and Copenhagen shares closing 4.7% higher at DKK 314.20. The rally followed an FDA filing for a higher-dose Wegovy, Medicare pricing clarity, and renewed interest in the company’s next-generation obesity drug. Despite the gains, Copenhagen shares remain down nearly 50% year-to-date.
26 November 2025
···
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer shares traded near $25.70 late Wednesday morning, down about 0.1%–0.2%. Zacks Research raised its 2025 earnings estimate for Pfizer to $3.15 per share, above Wall Street consensus. Thornburg Investment Management increased its Pfizer stake by 5.7% in Q2, now holding about 10.46 million shares. Pfizer’s next dividend payment is set for December 1.
26 November 2025
·
Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck shares closed Wednesday at $105.3, just below their 52-week high of $105.84, after a 0.3% dip. The stock has surged about 40% since late May, fueled by FDA approval of Keytruda and Padcev for bladder cancer and strong Q3 earnings. Trading volume reached nearly 3.9 million shares. Merck’s market cap stands above $260 billion.
26 November 2025
··
Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer closed Tuesday at $25.72, up nearly 2%, with a dividend yield of about 6.7% and a market cap near $146 billion. Unusual options activity clustered at the $25 strike followed new FDA approval for PADCEV plus Keytruda in bladder cancer and the completed Metsera obesity drug acquisition. Analyst target averages $28.56. Pfizer trades at a forward P/E of about 8.6, with 2025 total return up 3–4% year-to-date.
26 November 2025
··
Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck shares rose nearly 4% to $104–$105 in early afternoon trading Tuesday, nearing a 52-week high, after the FDA approved Keytruda plus Padcev for certain bladder cancer patients. The rally, boosted by a Wells Fargo upgrade and strong broker commentary, helped drive the Dow more than 400 points higher. Over 11 million Merck shares changed hands by midday.
25 November 2025
··
NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Novo Nordisk ADRs rose 4.7% to $47.08 in late trading Tuesday after mid-stage trial data showed its experimental obesity drug amycretin led to up to 14.5% weight loss in type 2 diabetes patients. The rebound follows a 5% drop Monday on failed Alzheimer’s trials. NVO remains down over 50% in the past year and trades near 52-week lows amid guidance cuts and competition from Eli Lilly.
25 November 2025
··
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly shares closed at $1,092.4 on Tuesday, up over 2%, after Bernstein raised its price target to $1,300 citing optimism for the obesity drug orforglipron. The stock’s market value stands near $1 trillion, with shares up more than 50% in three months and trading above the average analyst target. Trading volume was about 1.2 million shares.
25 November 2025
··
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics closed at $34.65 on November 24, valuing the company at about $3.9 billion. The firm completed enrollment in its Phase 3 obesity trial VANQUISH-1 ahead of schedule, with its lead drug VK2735 now in late-stage testing. Shares remain volatile, trading far below their 52-week high of $56.25 but well above the low of $18.92. Viking has no approved products or product revenue.
25 November 2025
··
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck shares climbed nearly 4% to around $101.40 by early afternoon Monday, nearing 2025 highs after Wells Fargo upgraded the stock to “Overweight” and raised its price target to $125. The move followed new FDA approvals and pipeline updates. Options activity surged, with call volume outpacing puts more than 3:1. Merck’s market cap stood at about $252 billion.
24 November 2025
··
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Bristol Myers Squibb shares rose 4.3% to $48.24 Monday after renewed investor interest in Factor XIa blood-thinner drugs and its candidate milvexian. The company announced a hematology-focused virtual investor event for December 11. Despite the gain, BMY remains down about 14% for the year, trailing the S&P 500’s 13.6% rise. Q3 earnings beat expectations, with revenue up 3% to $12.2 billion.
24 November 2025
·
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly became the first pharmaceutical company to reach a $1 trillion market capitalization, with shares trading near $1,058 on Monday. The surge follows strong demand for its weight-loss and diabetes drugs Mounjaro and Zepbound, both based on tirzepatide. Lilly’s stock has climbed over 35% in 2025 and more than 75% since Zepbound’s late 2023 launch. The company now trades at about 50 times expected earnings.
24 November 2025
···
1 … 31 32 33 34 35 … 40

Stock Market Today

  • 1 Stock Under $50 With Strong Growth Potential, 2 Facing Market Headwinds
    May 13, 2026, 9:53 PM EDT. Stocks priced between $10 and $50 offer unique long-term investment opportunities but come with risks. Alarm.com (NASDAQ:ALRM) trades at $47.67 with modest 8.4% billings growth and stagnant operating margins, signaling potential underperformance. Marcus & Millichap (NYSE:MMI), at $30.42, shows weak 1.9% annual revenue growth and poor free cash flow margins, raising concerns about its growth prospects. In contrast, IMAX (NYSE:IMAX) stands out with a $35.31 share price, boasting impressive 23.5% annual revenue growth and expanded free cash flow margins, indicating robust fundamentals and potential for long-term gains.

Latest articles

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

14 May 2026
USA Rare Earth reported Q1 revenue of $5.7 million and a net loss of $67 million, ending March with $1.75 billion in cash after a $1.5 billion PIPE. The company expects to sign documents this month for $1.6 billion in U.S. Commerce Department funding. Texas awarded a $14.18 million grant for the Round Top project. USA Rare Earth agreed in April to acquire Brazil’s Serra Verde for $2.8 billion.
Go toTop